GlobeNewswire

MediaPlatform at ISE 2018 to Showcase Award-Winning Enterprise Streaming Platform

Dela

Leader in Gartner Magic Quadrant to Demonstrate Webcasting and Video Content Management Capabilities

 

AMSTERDAM, The Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Integrated Systems Europe - 6-9 February 2018 - MediaPlatform (www.mediaplatform.com), the leading enterprise video platform enabling live webcasting and on-demand streaming, is pleased to announce its presence at Integrated Systems Europe (ISE), the world's largest audiovisual and system integrations conference.

MediaPlatform, a Leader in the Gartner Magic Quadrant and Forrester Wave, has a rising global presence, which has grown significantly in the past year, with noteworthy customer acquisitions and a rising sales presence in Europe and the EMEA region.

Among its growing customer base, MediaPlatform has acquired the business of Fortune 500 companies across the United States in the fields of research, finance and technology, as well as cementing its presence in Europe with a multi-billion-dollar technology manufacturer based in Switzerland. 

MediaPlatform To Showcase Enterprise Streaming and Unified Communication  Integrations

MediaPlatform will be showcasing its enterprise streaming platform, as well as its integration options for unified communications at ISE Amsterdam. Through seamless integrations with videoconferencing solutions, web conferencing tools and enterprise social platforms, MediaPlatform helps organizations create a single environment for creating internal corporate broadcasts, distributing on-demand media and managing enterprise video assets.

"It's exciting to share our award-winning platform and enterprise webcasting capabilities with the attendees of ISE," said Mike Newman, CEO, MediaPlatform. "It's a tremendous show and attendee base and, with all of the momentum and growth in enterprise webcasting and unified communications, it seems like the perfect time to increase our presence in the European market."

MediaPlatform To Showcase Agnostic Video Delivery for Enterprise Webcasting

MediaPlatform will also be providing demos of its new Unified Video Player for agnostic delivery of enterprise webcasting. The company's video player is the next step in the evolution of a product designed to meet the needs of organizations with plans to transition away from Flash, while remaining the most secure option for companies significantly invested in IP multicasting.

"I speak for everyone at MediaPlatform in saying how excited we are to be able to share our story around enterprise streaming at ISE. This show always brings together a great mix of cutting-edge solutions, products and technologies," said Jared Hawkins, VP Product, MediaPlatform.

In addition to demoing its award-winning enterprise video platform, MediaPlatform will be showcasing its integrations with proven technology providers to improve video content delivery and management. These include:

Skype for Business
The MediaPlatform integration with Skype for Business helps deliver interactive all-hands broadcasts to audiences of well over 10,000 live concurrent viewers and manage recordings in a secure and searchable enterprise video portal.

Polycom
MediaPlatform's interoperability with Polycom enables webcasting of video sessions to audiences of unlimited size, and seamless publishing of recordings to a secure video portal.

Cisco
For organizations leveraging the Cisco TelePresence Content Server (TCS), MediaPlatform enables video from Cisco-powered videoconferences to automatically stream to a live webcast, be archived, and be published to a secure video portal.

Pexip
MediaPlatform has partnered with Pexip to integrate the WebCaster live streaming solution with the Pexip Infinity platform to enable large-scale webcasting of virtual meetings.

WebEx
MediaPlatform's Cisco WebEx integrations provide organizations with a central and searchable repository for web conference recordings, online meetings and videoconferences.

MediaPlatform will be exhibiting in Hall 14 at Booth #14-K165 from 6-9 February 2018 at ISE Europe.

For more information, attendees can schedule a meeting to demo MediaPlatform's award-winning enterprise video solutions at ISE Europe here.

About MediaPlatform
MediaPlatform is a leading enterprise video platform enabling large-scale live streaming and on-demand video for executive messaging, e-learning, and collaboration. MediaPlatform provides a comprehensive set of products and services to help organizations leverage the power of video to improve employee engagement and enhance productivity. Organizations leveraging MediaPlatform's suite of products and services include Abbott Laboratories, Adobe, EY, Northwestern Mutual and Sprint.

www.mediaplatform.com

Media Contact:
Barry Canty
VP Marketing
MediaPlatform
bcanty@mediaplatform.com
(310) 909-8410




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MediaPlatform, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum